MediWound Ltd. (MDWD) Given a $9.00 Price Target by SunTrust Banks, Inc. Analysts

SunTrust Banks, Inc. set a $9.00 price objective on MediWound Ltd. (NASDAQ:MDWD) in a research report report published on Thursday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $10.00 price target on shares of MediWound in a research report on Monday, September 18th. ValuEngine lowered shares of MediWound from a sell rating to a strong sell rating in a research report on Friday, September 22nd. Zacks Investment Research raised shares of MediWound from a strong sell rating to a hold rating in a research report on Wednesday, August 2nd. Cowen and Company initiated coverage on shares of MediWound in a research report on Thursday, September 28th. They set an outperform rating and a $9.00 price target on the stock. Finally, Jefferies Group LLC reaffirmed a buy rating and set a $10.00 price target on shares of MediWound in a research report on Thursday, September 28th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $9.13.

MediWound (MDWD) opened at $4.60 on Thursday. MediWound has a 1-year low of $4.15 and a 1-year high of $8.25.

WARNING: “MediWound Ltd. (MDWD) Given a $9.00 Price Target by SunTrust Banks, Inc. Analysts” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/20/mediwound-ltd-mdwd-given-a-9-00-price-target-by-suntrust-banks-inc-analysts.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new position in shares of MediWound in the third quarter valued at about $2,140,000. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of MediWound by 9.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock valued at $11,882,000 after purchasing an additional 192,860 shares during the period. Nationwide Fund Advisors bought a new position in shares of MediWound in the third quarter valued at about $1,538,000. Wells Fargo & Company MN raised its position in shares of MediWound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the period. 27.12% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply